Figure 2.

Fixed-dose-rate gemcitabine in the cat. Cats (n = 15) with various malignancies received gemcitabine (dFdC) delivered as a fixed-dose rate infusion of 1 mg/m² per minute (A), 2.5 mg/m² per minute (B), 5 mg/m² per minute (C), and 10 mg/m² per minute (D) for 1 to 6 h. Plasma dFdU was quantitated in parallel. Prior to and at each hour during infusion, plasma was collected, deproteinated and then frozen at −80°C until analysis by HPLC. The data was plotted using a non-linear regression line as described in Materials and methods. The shaded area represents the target plasma concentration of gemcitabine in this study. Individual cats may be represented more than once and in more than one graph.